[Observation on serum γ-glutamyl transpeptidase levels of patients with subclinical schistosomiasis before and after pathogen treatment].

OBJECTIVE: To observe the changes of serum γ-glutamyl transpeptidase (GGT) levels before and after the pathogen treatment in patients with subclinical schistosomiasis, and explore its clinical value in the diagnosis and treatment of subclinical schistosomiasis. METHODS: Totally 109 patients with subclinical schistosomiasis, who were found in the endemic investigation of schistosomiasis in Ezhou City, were selected as the investigation subjects, and then they were treated with praziquantel. The serum GGT levels of the subjects before and after the treatment were detected and compared. RESULTS: Before the treatment, the average value of the GGT levels of the 109 patients was (48.1 ± 45.9) IU/L, among which, the GGT levels of 69 cases (63.3%) were normal, and the levels of 40 cases (36.7%) were increased. After the treatment, the average GGT level of the patients was (32.1 ± 23.4) IU/L, which decreased by 33.3% comparing with that before the treatment, and the difference had a statistical significance (U＝2.17, P = 0.01). The GGT levels of 65 patients decreased in different degrees. Among the 40 patients whose GGT levels had increased before the treatment, the GGT levels of 31 ones returned to the normal. CONCLUSIONS: The GGT level detection can accurately reflect the liver function in the patients with subclinical schistosomiasis, and also it has certain clinical application value to judge the liver function damage and recovery of the patients before and after the pathogen treatment.